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Abstract: 
The objective of this study is to assess the performance of four biological tests designed to 
detect recent HIV-1 infections in estimating incidence in West Africa (BED, Vironostika, 
Avidity, and IDE-V3). 
These tests were assessed on a panel of 135 samples from 79 HIV-1-positive regular blood 
donors from Abidjan, Côte d’Ivoire, whose date of seroconversion was known (ANRS 1220 
cohort). The 135 samples included 26 from recently infected patients (180 days), 94 from 
AIDS-free subjects with long standing infection (>180 days), and 15 from patients with 
clinical AIDS. The performance of each assay in estimating HIV incidence was assessed 
through simulations.  
The modified commercial assays gave the best results for sensitivity (100% for both), and the 
IDE-V3 technique for specificity (96.3%). In a context like Abidjan with a 10% HIV-1 
prevalence associated with a 1% annual incidence, the estimated test-specific annual 
incidence rates would be 1.2% (IDE-V3), 5.5% (Vironostika), 6.2% (BED) and 11.2% 
(Avidity). Most of the specimens falsely classified as incident cases were from patients 
infected for >180 days but <1 year.  
Authors conclude that None of the four methods could currently be used to estimate HIV-1 
incidence routinely in Côte d’Ivoire, but further adaptations might enhance their accuracy. 
 
Keywords: HIV incidence, STARHS assay, surveillance, Africa, recent infection, 
immunoassay. 
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Introduction 
In sub-Saharan Africa, the human immunodeficiency virus type-1 (HIV-1) epidemic has been 
fast growing for more than two decades [1]. To monitor its trend, two indicators are required: 
the prevalence, which estimates the number of people living with HIV infection at a given 
time, and the incidence, which estimates the number of new infections during a given time 
interval. In Africa, surveillance systems have focused on estimating the HIV-1 prevalence 
through serological testing of samples collected from sentinel populations, while the HIV 
incidence rate has rarely been estimated. However, estimates of incidence rates are essential 
for understanding the natural dynamics of the epidemic as well as for measuring the impact of 
prevention strategies.  
 
Direct measurement of HIV incidence through large prospective cohort studies with repeated 
HIV antibody testing of the participants has been the gold standard to estimate the rate of 
acquisition of new infections. However, such studies are very expensive, time consuming, 
may be subject to participation bias, and are logistically difficult to implement, especially in 
the African context. Therefore, only a handful of such community-based prospective surveys 
have been undertaken so far [2-5].  
Mathematical models have been developed to estimate incidence using single or serial age-
specific prevalence data and survival distribution after HIV-1 infection [6-11]. Although these 
methods are of great interest and give age and time trends of HIV-1 incidence, they require 
assumptions which lead to unavoidable uncertainty in point estimates [12]. Furthermore, they 
were designed in settings where patients had limited or no access to care and treatment, a 
situation which will hopefully become increasingly rare with the scaling-up of treatment 
programs in Africa [13]. 
 
 5 
Over the past decade, for the purpose of estimating HIV incidence, a number of enzyme-
immuno assays (EIA) have been developed to differentiate between recent and long-standing 
HIV-infections [14-20]. These methods rely on features of the evolving HIV-1 antibody 
response during the months following primary HIV-1 infection. Some of these methods have 
found wide acceptance. For instance the IgG capture BED EIA assay [15] is being used by the 
US Centers for Disease Control and Prevention (CDC) to estimate national HIV-1 incidence 
in the USA, superseding the so-called ‘detuned’ assay [14, 17] that has been used by many 
groups to estimate HIV incidence in specific population groups [21-23]. In France, the 
technique developed by Barin et al [19] is now routinely used during the ‘mandatory 
notification’ of HIV infection [24]. An antibody avidity assay has also been developed and is 
being routinely used in Italy [25]. Each of these approaches takes advantage of different 
features of the early immune response to HIV infection, though all were developed with 
antigens derived from HIV-1 subtype B only, or B, E and D, and are thus optimised for 
populations among which these subtypes predominate, such as those of America, Asia and 
Europe. By contrast, these techniques have had only limited evaluation on specimens from 
Africa where HIV-1 incidence is generally higher and where non-B subtypes predominate.  
The objective of the present study was to assess the performance of four tests devised to 
detect recent infections (TRI) in estimating HIV-1 incidence in West Africa. The assessment 
utilised a panel of specimens from HIV-1 seroconverters enrolled in the ANRS 1220 PRIMO-
CI cohort with a known date of infection [26], and mainly infected with HIV-1 CRF02_AG 
strains in Abidjan, Côte d’Ivoire, West Africa [27].  
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Material and methods 
Laboratory methods 
In our study, four assays that identify recent HIV-1 infections were assessed: one assay 
commercialised by Calypte Biomedical Corporation (Rockville, Maryland, USA), the IgG-
capture BED-EIA (BED) [15]; two modified commercial assays: the Vironostika HIV-1 EIA 
from BioMerieux, Raleigh, NC, USA (Vironostika) [16, 17]; and the Abbott HIV1 1/2gO 
assay modified by Suligoi et al to assess the avidity of anti-HIV (Avidity) [18]; and an in-
house assay developed by Barin et al [19], the IDE-V3 EIA. With the exception of the avidity 
assay the results were quantitative ratios calculated as optical densities obtained with serum 
specimens divided by the assay cut-off which was derived from the reactivity of controls 
and/or calibrators incorporated in each run. The avidity assay provides a quantitative result 
based on the relative signal given by the specimen with and without treatment with a 
chaotropic agent (1M guanidine). Each approach employs a defined cut-off and window 
period which allows the distinction of recent from non-recent infections. The exact methods 
for the performance, standardization and interpretation of each assay have been described 
previously [15, 17, 19, 25]. Table 1(A) summarizes the cut-offs employed for each of the TRI, 
the associated window periods during which recent infection can be inferred, and the 
sensitivity and specificity estimates that have been described in the literature for each of the 
four tests. These values were established and validated on Caucasian populations harbouring a 
predominance of HIV-1 subtype B viruses. For the BED method, we applied the window 
period of 160 days and the associated cut-off of 1.0 to be closer to the other TRI window 
periods and for the Avidity test, we used the 0.85 cut-off as it is the one that has been selected 
[28] and used as previously described [29].  
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Study population and samples 
We used data from the ANRS 1220 PRIMO-CI cohort, constituted of HIV-1 and HIV-1+2 
positive regular blood donors with a known or estimated date of sexual transmission [26]. 
Enrolment into this cohort began in June 1997 and involved 199 individuals as of December 
2003. In the present study, the four above mentioned TRIs were assessed on 135 serum 
samples from 79 cohort subjects. All selected specimens were sent to the virology laboratory 
in Tours, France, where the IDE-V3 immunoassay was carried out. The Vironostika, BED and 
Avidity assays were performed in the Virus Reference Department of the Health Protection 
Agency Centre for Infections, London, UK.  
The window period associated with TRI x (x could be either BED, Vironostika, IDE-V3, or 
Avidity) is denoted by the symbol x. Samples were defined as ‘recently infected’ if the time 
elapsed between their last negative HIV serological result and their first positive result, 
obtained on specimens taken at inclusion in the cohort, was ≤ x. Individuals for whom this 
same interval exceed x were assumed not to have been infected recently (established 
infection). The selection criteria for serum specimens were as follows: (i) all available 
samples taken at recruitment in the ANRS 1220 PRIMO-CI cohort from subjects defined as 
recently infected, i.e. with the time period between last HIV-negative test and sample <x. 
However, the number of recently infected samples available differed according to the window 
period, x, defined for each TRI employed. Indeed, for the TRI with the longest window, 
x=180 days, there were 26 samples which met the definition for recent infection. Two of 
these were not suitable for the definition of recent infection with the window period x=170 
days (n=24), and only 14 of them were suitable with the window period x=160; (ii) 94 
specimens from asymptomatic subjects with established infection; and (iii) 15 specimens from 
subjects who were diagnosed with clinical AIDS. Among the 109 specimens from patients 
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infected for >180 days, 27 were infected for 181-365 days, and 70 for more than one year. 
The 12 remaining specimens could not be classified within one of the two previous groups as 
the time period between their last negative HIV test and the date of sampling was too large 
(>one year), while the period between their first positive HIV test and the date of sampling 
was too short (<one year).  
 
Statistical methods 
The sensitivity (in our case, the ability to correctly classify as recent infection a patient 
infected with HIV in the past x days) and the specificity (the ability to classify a patient 
infected for more than x days as having a non-recent infection) were calculated for each test 
from the samples described above.  
In order to investigate the adequacy of the window period of each TRI to our sample, we 
categorised non-recent infections according to two time durations since infection: i) those 
infected >180 days but 1 year, ii) those infected for >1 year, and calculated the specificity 
for each group. 
The adequacy of the cut-offs were assessed using receiver operating characteristic (ROC) 
curves. The ROC curve represent the sensitivity by (1-specificity) plotted considering each 
quantitative value of the TRI as a possible cut-off to set apart recent from non-recent 
infections.  
 
Although the performance of the tests in estimating incidence depends on their sensitivity and 
specificity, the link is not straightforward as, when estimating a population incidence, a false 
negative can be compensated for by a false positive. This can lead to an accurate number of 
recent infections overall, though the individual diagnosis may not be correct. The ultimate 
goal of a TRI is usually to estimate incidence from a cross-sectional survey. We can not 
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directly assess the ability of the TRIs to estimate incidence as we do not have a sample with 
known incidence rate to which we could apply the TRIs and compare the true incidence with 
the estimated. Therefore, we simulated such populations with values for prevalence P and 
incidence I, and calculated the incidence that would be estimated with each TRI, according to 
its sensitivity and specificity characteristics that had been derived from their evaluation 
against the specimen panel described above.  
Let denote Ninc=number of recent infections, Nneg=number of HIV seronegative individuals, 
Npos=number of HIV-1 antibody positive subjects in the survey obtained using a standard HIV 
test, N=Npos+Nneg, and  k=365/ to allow results to be annualised . 
Surveys simulated of size N=135 were constructed as follows: from the true prevalence, we 
deduced the number of HIV negative subjects in the survey: posneg N
P
PN .1 . From the true 
incidence, we deduced the number of new infections in the survey: 
)2/1( Ik
INN neginc

  .  
For each TRI, the incidence estimated in the simulated survey was calculated as follows: the 
number dinc of new infections that would be diagnosed in the simulated survey was calculated 
using the following relation: )).(1(. incposincinc NNSpNSed  , where Se and Sp are the 
sensitivity and specificity of the TRI. We deduced the estimated incidence for each TRI using 
the consensus formula agreed upon at the US CDC for calculating incidence from a cross-
sectional survey [30]: 
2/.
.
incneg
inc
est
dkN
dk
I

 .  
This can be written as a function of the true prevalence P and incidence I in the simulated 
sample, and the sensitivity and specificity of the TRI, by replacing dinc using the relations 
given above, and finally: 
2/))]2/1.(.)(1()1)(1.([)2/1).(1(
))2/1.(.)(1()1)(1.(
IkPSpSpSePIIP
IkPSpSpSePI
I est


         (a) 
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It is clear from the formula (a) that the incidence estimated depends on the sensitivity and 
specificity of the test, as expected, but also on the real prevalence and incidence of HIV in the 
population sample. Therefore, we simulated different scenarios of surveys with given P and I 
in a population, and calculated the estimated incidence using each test with the formula (a), 
and compared it to the simulated incidence by calculating the relative bias 
I
II est .  
The estimated variance of the incidence is Iest
2
/dinc [30]; this variance is used to calculate the 
95% confidence intervals using the Normal approximation. 
 
Results 
Performance in individual detection of recent infection 
Table 1(B) summarizes the analytical performance of the four tests in detecting recent 
infections derived from applying them to our Abidjan specimen panel. In terms of sensitivity, 
the Vironostika and the Avidity tests gave the best results (both 100%), whereas the IDE-V3 
technique performed poorly (42.3%). However, in terms of specificity, the IDE-V3 was the 
most powerful (96.3%) whereas the Avidity showed the worst result (49.5%). The 15 patients 
with AIDS were all classified as non recent infections by three tests (Vironostika, BED and 
IDE-V3), while five were misclassified by the Avidity test (figure 1) which had the poorest 
specificity.  
 
Suitability of the window periods  
For each of the four TRI, the specificity was much higher when calculated only on those 
specimens collected from individuals infected for more than one year (table 2). This was 
especially true for the Vironostika and the BED tests whose specificity increased from 44% to 
93% and from 48% to 89% respectively. 
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Suitability of the cut-offs  
The ROC curves associated with each TRI are shown in figure 2, with arrows indicating the 
cut-offs used based on manufacturers’ recommendations or previous published reports. It is 
apparent from these graphs that the recommended cut-offs might not be the most appropriate 
ones on the samples from Abidjan. For example, with the Vironostika and Avidity assays, a 
lower cut-off would improve greatly the specificity without a corresponding magnitude of 
loss of sensitivity. The Vironostika gave the highest area under ROC curve (0.96), indicating 
its potential to provide the best balance of sensitivity and specificity. 
 
Performance in estimating incidence:  
The incidence figures estimated with each TRI according to several simulations of incidence 
and prevalence in a population, are presented in table 3. The situations where the simulated 
incidence falls within the confidence intervals of the estimated incidence are in bold. This 
happened only with the method with the best specificity (IDE-V3), and only in those 
scenarios for which the simulated incidence was high relative to the prevalence. When the 
simulated incidence is low compared to the prevalence, the incidence can be greatly 
overestimated by the TRI. For example, in a population with a 30% prevalence and 1% 
incidence, the over-estimation of incidence was 3 times with the IDE-V3 test, 17 times with 
the Vironostika, 20 times with the BED, and 36 times with the Avidity assay (table 3). For a 
given prevalence, and for all the TRIs, the bias in the estimated incidence increases when the 
simulated incidence decreases. This means that the tests can not be used reliably to monitor 
the time trends of incidence as, with a constant prevalence over time, it would underestimate a 
decrease in incidence, or overestimate an increase. For example, in a setting like Abidjan with 
a prevalence about 10% [31] and incidence around 1% [11], if HIV incidence is halved (that 
is a 50% relative decrease with the incidence going down to 0.5%) and if the prevalence 
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remains stable, all four methods would fail to identify the decrease in incidence: the BED 
would estimate the incidence to decrease from 6.2 to 5.9% (that is a 5% relative decrease), the 
Vironostika from 5.5 to 5.1% (that is a 7% decrease), the IDE-V3 from 1.2 to 1.0% (a 17% 
relative decrease), and the Avidity from 11.2 to 11% (a 2% relative decrease). 
 
 
Discussion 
This study is the first to assess these four reference assays for the detection of recent HIV-1 
infections among a West African population. We have shown that none of the four methods 
can be used in their present form on Abidjan’s population to provide accurate point estimates 
of incidence or follow trends in incidence.  
On the basis of our findings on the poor specificity among patients infected for more than 180 
days but less than one year (table 2), it is likely that our results are pessimistic in terms of 
specificity compared to a general HIV-infected population. Indeed, among the 109 selected 
specimens from patients infected for more than 180 days, 27 (25%) were from patients 
infected for less than one year, which is the period with the poorest specificity. Although it is 
difficult to know what would be the distribution of time since infection among a randomly 
selected sample of the general population, it is likely that this borderline population was over-
represented in our sample of seroconverting blood donors. For example, if we suppose that 
the number of new infections is constant over a 12-month period, when the prevalence is 10% 
and the incidence 1% as it has been previously estimated in Abidjan [11], there should be 
about 4.5% of the non-recently infected individuals infected for less than one year. 
Nevertheless, even if we take an optimal sample, that is when all the non-recent infections are 
older than 1 year, the specificity of each of the TRIs is still lower than the specificity of the 
IDE-V3 test on the overall sample (table 2), and this will lead to biased estimates of 
 13 
incidence. This emphasises that although our validation sample probably over-represents the 
frequency of infections of 6-12 months duration, this does not provide an explanation for the 
overall bias obtained when estimating incidence.  
 
Adjustment to improve the estimations 
One approach to circumvent the problem of imperfect specificity and sensitivity is to use a 
coefficient to adjust for misclassification as proposed by Parekh et al [15]. The incidence 
would then be estimated as follows: 
2/..
..
incneg
inc
NkFN
NkF
I

 , 
where 
)1(
1



SpSeP
SpP
F
obs
obs
  and   
N
N
P incobs   
The variability of this estimate depends on the variability of the sensitivity and specificity 
used. In the case where the sensitivity and specificity are not properly estimated, this 
correction could result in more harm than good, and even lead to negative incidence estimates 
when Pobs+Sp<1. Taking a population resembling Abidjan, with a 10% prevalence and 1% 
incidence, the IDE-V3 test estimates the incidence to be 1.2% (table 3). If the specificity of 
this test is overestimated to the upper limit of its confidence interval, that is 99.5% instead of 
96.3% (table 1(B)), the incidence estimated with the correction coefficient F would be 2.6%. 
If, on the other hand, the specificity of this test was underestimated to the lower limit of its 
confidence interval, that is 93% instead of 96.3% (table 1(B)), the incidence estimated with 
the correction coefficient F would be –0.9%. Both these estimations are further away from the 
real incidence than the non-corrected one and, moreover, one of them is negative. We 
conclude therefore, that this adjustment should be used with caution, and only when the 
sensitivity and specificity are well established. 
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Adaptation of the tests 
We have shown that the TRI with the best specificity gave the best incidence estimations 
(table 3). Raising the specificity of the TRIs would ameliorate their ability to estimate 
incidence.  
The specificity of each of the four TRI investigated was shown to be poor (i.e. designed 
specimens as incident) during the six months following the described window period 
(table 2). These results suggest that a longer window period might be more appropriate to the 
Abidjan specimens. Furthermore, we showed that the cut-offs associated with each test 
validated on Caucasian samples might not be appropriate to African ones and should be re-
evaluated, especially for the Vironostika and the Avidity methods (figure 2), in favour of 
improved specificity. 
 
Differences in the response to HIV infection may exist between the Caucasian population 
amongst which the methods were originally developed and validated and the population of 
Abidjan, and this deserves further investigation. Some differences between African and 
European immune response to HIV have been reported already, especially concerning CD4 
counts [32, 33]. Sera from AIDS cases were correctly classified as non-recent infection in the 
Abidjan study sample, with the exception of the Avidity method (figure 1), while it frequently 
led to a false positive diagnosis in the Caucasian population. Although this result correlates 
with a sustained anti-p24 antibody response among African patients, but not among 
Caucasians, when they progress to AIDS [34], it is a new information that should be validated 
on larger population samples of various origins.  
The circulating viruses are predominantly subtype B in Europe and USA, and non-B, 
particularly CRF02_AG, in West Africa. The difference in subtypes may be responsible for 
some performance loss, indeed, different performance characteristics in detecting recent 
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infections among individuals infected with subtypes B, A/D, C or E using BED or 
Vironostika methods have already been reported [20, 35]. This may be due to subtle 
differences in the binding of antibodies generated against infection with non-B subtypes of 
HIV with antigens derived predominantly from subtype B viruses, as utilised in most 
diagnostic tests. Alternatively, one could relate the differences of performance in different 
populations to the genetic background, or to environmental factors that may influence the 
immune response. Indeed, total IgG levels are known to be significantly elevated among 
African, and malnutrition, common in Africa, has been linked to immunological dysfunction 
[36, 37]. Such factors might be responsible for some of the performance differences but these 
hypotheses need further investigations. 
 
Using a TRI to estimate incidence of HIV-1 infection remains a very attractive solution to 
monitor the epidemic on the African continent. Many countries already have a sero-
surveillance system, and adding a TRI to the surveillance protocol would be simple and low-
cost [38]. However, further investigations are needed to adapt the existing TRIs. Our data 
would indicate that the use of a longer window period, and/or a different cut-off favouring a 
better specificity might improve their accuracy in estimating HIV incidence. Also the size of 
the sample used in this study provides insufficient power to allow the definition of better 
adapted cut-offs and/or window periods. To bring together several cohorts of patients with 
known date of infection from various part of Africa, if possible including patients whose 
infection subtypes are characterized, is a necessary step to adapt the existing methods to 
permit accurate detection of recent infections on its continent. Our conclusion and 
recommendation support the recently released UNAIDS/WHO warning on the routine 
surveillance use of BED test and the need for further research on the matter [39]. 
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Table 1. Cut-offs, window periods, sensitivity and specificity associated with each of the four 
tests used to detect recent HIV infections. 
Assay Cut-off Window 
period 
Sensitivity  
(95% CI) 
Specificity 
(95% CI) 
N(RI-NRI)
*
 
(A) Published performances 
BED [15] 1.0 
0.8 
160 
153 
82.7% 97.8%  
Vironostika [16, 17] 1.0 170 97% >98%  
IDE-V3 [19] 0.5 180 88.3% 97.6%  
Avidity [25] 0.6 
0.7 
0.8 
0.9 
180 26.4% 
61.8% 
79.4% 
88.2% 
98.9% 
95.1% 
92.3% 
86.8% 
 
(B) Calculated performances on the samples from Abidjan 
BED 1 160 85.7% (79-92) 77.1% (70-84) 123(14-109) 
Vironostika 1 170 100% (86-100) 79.8% (73-87) 133(24-109) 
IDE-V3 0.5 180 42.3% (34-51) 96.3% (93-99) 135 (26-109) 
Avidity 0.85 180 100% (87-100) 49.5% (41-58) 135 (26-109) 
* N= sample size, RI=number of recent infections, NRI=number of non recent infections 
CI: confidence interval 
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Table 2: Distribution of false positive diagnosis of recent HIV infection according to time since infection groups, and associated specificity  
Time since infection BED Vironostika IDE-V3 Avidity 
 
False 
positive 
Specificity 
False 
positive 
Specificity 
False 
positive 
specificity 
False 
positive 
specificity 
180 days to 1 year, n=27 14 48.2% 15 44.4% 4 85.2% 18 33.3% 
More than 1 year, n=70 8 88.6% 5 92.9% 0 100% 29 58.6% 
Total NRI, n=109 25 77.1% 22 79.8% 4 96.4% 55 49.5% 
NRI: non-recent infections. 
False positive : number of non-recent infections classified as recent. 
Specificity: proportion of non-recent infections properly diagnosed. 
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Table 3 : HIV incidence estimated with each test for recent infection (TRI), according to prevalence and incidence in the simulated populations. 
Population BED Vironostika IDE-V3 Avidity 
Prevalence Incidence Est. incidence (CI) Bias
*
 Est. incidence (CI) Bias
*
 Est. incidence (CI) Bias
* 
Est. incidence (CI) Bias
*
 
          
30% 10% 25.3% (17-30) 153% 23.8% (16-28) 138% 7.0% (3-10) -30% 39.4% (31-44) 294% 
30% 5% 22.7% (15-27) 354% 20.4% (13-25) 307% 5.1% (2-7) 1% 37.7% (29-42) 654% 
30% 1% 20.6% (13-25) 1964% 17.7% (11-22) 1668% 3.5% (0.6-6) 254% 36.3% (28-41) 3532% 
          
10% 5% 8.6% (6-10) 73% 8.5% (6-10) 71% 2.8% (1-4) -45% 13.0% (10-15) 160% 
10% 1% 6.2% (4-8) 524% 5.5% (4-7) 447% 1.2% (0.3-2) 21% 11.2% (9-13) 1021% 
10% 0,50% 5.9% (4-7) 1088% 5.1% (3-6) 917% 1.0% (0.2-2) 104% 11.0% (8-13) 10710% 
          
5% 1% 3.3% (2-4) 232% 3.0% (2-4) 204% 0.8% (0.3-1.1) -22% 5.7% (4-7) 472% 
5% 0,50% 3.0% (2-4) 504% 2.6% (2-3) 429% 0.6% (0.2-0.9) 17% 5.5% (4-6) 997% 
5% 0,10% 2.8% (2-4) 2673% 2.3% (1-3) 2235% 0.4% (0.1-0.7) 333% 5.3% (4-6) 5195% 
* Relative bias : (Iest-I)/I 
Est. incidence (CI): estimated incidence calculated as described in the method section, and confidence intervals. 
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Figures titles: 
 
Figure 1: Distribution of the quantitative results obtained with each test according to the HIV infection category (RI: recent infection, NRI: non 
recent infection, AIDS: AIDS stage). The horizontal lines represent the recommended cut-off associated with the method. ANRS 1220 Cohort, 
Abidjan, Côte d’Ivoire. 
 
 
Figure 2 : ROC curves associated with each test of recent HIV-1 infection. The arrows indicate the recommended cut-off values. ANRS 1220 
Cohort, Abidjan, Côte d’Ivoire. 
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Figure 1 :.   
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